NeuroSense Therapeutics
NRSN
7 hedge funds and large institutions have $733K invested in NeuroSense Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 5 closing their positions.
6% more capital invested
Capital invested by funds: $694K → $733K (+$39K)
0.32% more ownership
Funds ownership: 1.54% → 1.86% (+0.32%)
22% less funds holding
Funds holding: 9 → 7 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$94.2K |
| 2 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
+$75.1K |
| 3 |
Jane Street
New York
|
+$64K |
| 4 |
Millennium Management
New York
|
+$38.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$397K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$65K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$48K |
| 4 |
FIA
FNY Investment Advisers
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $261K | +$64K | +33,751 | +78% |
|
|
2
Citigroup
New York
| $168K | +$94.2K | +49,734 | +497,340% |
|
|
VPIM
3
Vanguard Personalized Indexing Management
Oakland,
California
| $134K | +$75.1K | +39,634 | New |
|
|
4
Millennium Management
New York
| $68K | +$38.4K | +20,259 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $45K | +$21.9K | +11,544 | +613% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $33K | +$18K | +9,494 | +3,165% |
|
|
CS
7
Clear Street
New York
| $24K | +$13.6K | +7,157 | New |
|
|
IC
8
Ikarian Capital
Dallas,
Texas
| – | -$397K | -100,000 | Closed |
|
|
BFM
9
Boothbay Fund Management
New York
| – | -$48K | -12,170 | Closed |
|
|
10
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$65K | -10,000 | Closed |
|
|
FIA
11
FNY Investment Advisers
New York
| – | -$3K | -1,000 | Closed |
|
NRSN Hedge Fund Activity: Q2 2022 in Review
7 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2022, worth a combined $733K — up 5.6% from $694K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NRSN and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 4 added.
The largest buyer was Citigroup, adding an estimated $94.2K. The largest seller was Ikarian Capital, exiting entirely with an estimated $397K sold.
- 7 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2022, down from 9 in Q1 2022.
- Funds reported $733K of NeuroSense Therapeutics stock for Q2 2022, up 5.6% quarter-over-quarter.
- 3 funds opened new NeuroSense Therapeutics positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest NeuroSense Therapeutics buyer in Q2 2022 was Citigroup, an estimated $94.2K added.
- The largest NeuroSense Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $397K sold.
Based on aggregated 13F filings for Q2 2022.